LAVA Therapeutics (US:LVTX) — Company Overview, News & Financial Data

LAVA Therapeutics NV (NASDAQ:LVTX) is a biotech firm focused on harnessing the power of its proprietary platform to develop a novel class of bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of cancer. With a unique approach to cancer immunotherapy, LAVA targets a wide range of tumors by activating an innate immune response that is designed to selectively kill cancer cells. The company's pipeline is made up of several projects in varying stages of preclinical and clinical development, aiming to address the needs of patients with hard-to-treat cancers. LAVA Therapeutics is committed to pushing the boundaries of cancer treatment through ongoing research and development efforts, with the ultimate objective of improving patient outcomes and providing new therapeutic options for cancers with significant unmet medical needs.